Investigational drug · Phase 3
JNJ-81201887
Also called: AAVCAGsCD59
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Geographic Atrophy, Macular Degeneration.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "JNJ-81201887"
First trial start
2023
Mar 6, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JNJ-81201887", any sponsor or status.
Conditions studied
As listed on its trial records.
- Geographic Atrophy
- Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Geographic atrophy · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "JNJ-81201887" as an intervention, largest first.
- A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)Pivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05811351 · 305 participants · Start Mar 6, 2023 · Primary completion Feb 23, 2026
Drug: JNJ-81201887; Prednisone and 1 more · For: Geographic Atrophy
Sites: Phoenix, Arizona; Tucson, Arizona; Fullerton, California · 162 sites in all
- A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)Pivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06635148 · 274 participants (planned) · Start Sep 19, 2024 · Primary completion Aug 24, 2029
Drug: JNJ-81201887 · For: Geographic Atrophy; Macular Degeneration
Sites: Tucson, Arizona; Fullerton, California; La Jolla, California · 104 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Heier JS, Cohen MN, Chao DL, et al. · Ophthalmology 2024
Also in development for Geographic Atrophy
- TinlarebantLBS-008Phase 33 trials
Belite Bio, Inc · Stargardt Disease 1, STGD1, Geographic Atrophy
- VonaprumentANX007Phase 32 trials
Annexon, Inc. · Geographic Atrophy
- OpRegenPhase 22 trials
Roche (Genentech) · Age-Related Macular Degeneration, Geographic Atrophy
- STL303Phase 22 trials
Sitala Bio LTD · IgAN, Geographic Atrophy
- ABBV-6628Phase 21 trial
AbbVie · Geographic Atrophy, Age-Related Macular Degeneration
- BI 1584862Phase 21 trial
Boehringer Ingelheim · Geographic Atrophy
- BI 771716Phase 21 trial
Boehringer Ingelheim · Macular Degeneration, Age-related, Geographic Atrophy
- BRX011Phase 21 trial
Biojiva LLC · Geographic Atrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.